[1]
|
S. G. Satko, J. R. Sedor, S. K. Iyengar and B. I. Freedman, “Familial Clustering of Chronic Kidney Disease,” Seminars in Dialysis, Vol. 20, No. 4, 2007, pp. 229-236.
doi:10.1111/j.1525-139X.2007.00282.x
|
[2]
|
C. S. Fox, Q. Yang, L. A. Cupples, C. Y. Guo, M. G. Larson, E. P. Leip, et al., “Genome Wide Linkage Analysis to Serum Creatinine, GFR, and Creatinine Clearance in a Community-Based Population: The Framingham Heart Study,” Journal of the American Society of Nephrology, Vol. 15, No. 9, 2004, pp. 2457-2461.
doi:10.1097/01.ASN.0000135972.13396.6F
|
[3]
|
P. P. Faronato, M. Maioli, G. Tonolo, E. Brocco, F. Noventa, F. Piarulli, et al., “Clustering of Albumin Excretion Rate Abnormalities in Caucasian Patients with NIDDM. The Italian NIDDM Nephropathy Study Group,” Diabetologia, Vol. 40, No. 7, 1997, pp. 816-823.
doi:10.1007/s001250050754
|
[4]
|
W. M. McClellan, S. G. Satko, E. Gladstone, J. O. Krisher, A. S. Narva and B. I. Freedman, “Individuals with a Family History of ESRD Are a High-Risk Population for CKD: Implications for Targeted Surveillance and Intervention Activities,” American Journal of Kidney Diseases, Vol. 53, Suppl. 3, 2009, pp. S100-S106.
|
[5]
|
J. Coresh, E. Selvin, L. A. Stevens, J. Manzi, J. W. Kusek, P. Eggers, et al., “Prevalence of Chronic Kidney Disease in the United States,” Journal of the American Medical Association, Vol. 298, No. 17, 2007, pp. 2038-2047.
doi:10.1001/jama.298.17.2038
|
[6]
|
Q. L. Zhang and D. Rothenbacher, “Prevalence of Chronic Kidney Disease in Population-Based Studies: Systematic Review,” BMC Public Health, Vol. 8, 2008, pp. 117.
doi:10.1186/1471-2458-8-117
|
[7]
|
M. K. Haroun, B. G. Jaar, S. C. Hoffman, G. W. Comstock, M. J. Klag and J. Coresh, “Risk Factors for Chronic Kidney Disease: A Prospective Study of 23,534 Men and Women in Washington Country, Maryland,” Journal of the American Society of Nephrology, Vol. 14, No. 11, 2003, pp. 2934-2941.
doi:10.1097/01.ASN.0000095249.99803.85
|
[8]
|
F. C. Luft, “Hypertensive Nephrosclerosis: Update,” Current Opinion in Nephrology and Hypertension, Vol. 13, No. 2, 2004, pp. 147-154.
doi:10.1097/00041552-200403000-00002
|
[9]
|
B. I. Freedman, S. S. Iskandar and R. G. Appel, “The Link between Hypertension and Nephrosclerosis,” American Journal of Kidney Diseases, Vol. 25, No. 2, 1995, pp. 207-221. doi:10.1016/0272-6386(95)90001-2
|
[10]
|
C. Y. Hsu, “Does Non-malignant Hypertension Cause Renal Insufficiency? Evidence-Based Perspective,” Current Opinion in Nephrology and Hypertension, Vol. 11, No. 3, 2002, pp. 267-272.
doi:10.1097/00041552-200205000-00001
|
[11]
|
J. A. Sarnak, T. Greene, X. Wang, G. Beck, J. W. Kusek, A. J. Collins, et al., “The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-Up of the Modification of Diet in Renal Disease Study,” Annals of Internal Medicine, Vol. 142, No. 5, 2005, pp. 342-351.
|
[12]
|
A. Siewert-Delle, S. Ljungman, O. K. Andersson and L. Wilhelmsen, “Does Treated Primary Hypertension Lead to End-Stage Renal Disease? A 20-Year Follow-Up of the Primary Prevention Study in G?teborg, Sweden,” Nephrology Dialysis Transplantation, Vol. 13, No. 12, 1998, pp. 3084-3090. doi:10.1093/ndt/13.12.3084
|
[13]
|
C. Y. Hsu, C. E. McCulloch, J. Darbinian, A. S. Go and C. Iribarren, “Elevated Blood Pressure and Risk of End-Stage Renal Disease in Subjects without Baseline Kidney Disease,” Archives of Internal Medicine, Vol. 165, No. 8, 2005, pp. 923-928. doi:10.1001/archinte.165.8.923
|
[14]
|
L. Zarif, A. Covic, S. Iyengar, A. R. Sehgal, J. R. Sedor and J. R. Schelling, “Inaccuracy of Clinical Phenotyping Parameters for Hypertensive Nephrosclerosis,” Nephrology Dialysis Transplantation, Vol. 15, No. 11, 2000, pp. 1801-1807. doi:10.1093/ndt/15.11.1801
|
[15]
|
R. B. Toto, “Hypertensive Nephrosclerosis in African Americans,” Kidney International, Vol. 64, No. 6, 2003, pp. 2331-2341. doi:10.1046/j.1523-1755.2003.00333.x
|
[16]
|
R. Marín, M. Gorostidi, F. Fernández-Vega and R. álvarez-Navascués, “Systemic and Glomerular Hypertension and Progression of Chronic Renal Disease: The Dilemma of Nephrosclerosis,” Kidney International Supplements, Vol. 99, Suppl. 99, 2005, pp. S52-S56.
doi:10.1111/j.1523-1755.2005.09910.x
|
[17]
|
W. M. McClellan, S. G. Satko, E. Gladstone, J. O. Krisher, A. S. Narva and B. I. Freedman, “Individual with a Family History of ESRD Are a High Risk Population for CKD: Implications for Targeted Surveillance and Intervention Activities,” American Journal of Kidney Diseases, Vol. 53, Suppl. 3, 2009, pp. S100-S106.
doi:10.1053/j.ajkd.2008.07.059
|
[18]
|
W. H. Kao, M. J. Klag, L. A. Meoni, D. Reich, Y. Berthier-Schaad, M. Li, et al.,“MYH9 is Associated with Nondiabetic End Stage Renal Disease in African Americans,” Nature Genetics, Vol. 40, No. 10, 2008, pp. 1185-1192.
doi:10.1038/ng.232
|
[19]
|
K. Anbazhagan, K. Sampathkumar, M. Ramakrishnan, S. Gomathi and G. S. Selvam, “Analysis of Polymorphism in Renin Angiotensin System and Other Related Genes in South Indian Chronic Kidney Disease Patients,” Clinica Chimica Acta, Vol. 406, No. 1-2, 2009, pp. 108-112.
doi:10.1016/j.cca.2009.06.003
|
[20]
|
J. Xu , G. Li, P. Wang, H. Velazquez, X. Yao, Y. Li, et al., “Renalase Is a Novel, Soluble Monoamine Oxidase that Regulates Cardiac Function and Blood Pressure,” Journal of Clinical Investigation, Vol. 115, No. 5, 2005, pp. 1275-1280.
|
[21]
|
G. V. Desir, “Regulation of Blood Pressure and Cardiovascular Function by Renalase,” Kidney International, Vol. 76, No. 2009, pp. 366-370. doi:10.1038/ki.2009.169
|
[22]
|
G. Desir, P. Wang and H. Velazquez, “On the Mechanisms Mediating the Cardioprotective Effect of Renalase,” Journal of the American Society of Nephrology, 2009.
http://www.asn-online.org/education_and_meetings/renal_week/archives/
|
[23]
|
S. S. Ghosh, T. W. B. Gehr and D. A. Sica, “Renalase Regulates Blood Pressure in Salt Sensitive Dahl Rats,” Journal of the American Society of Nephrology, Vol. 17, 2006, p. 208A.
|
[24]
|
G. Desir, L. Tang, P. Wang, G. Li and H. Velazquez, “Antihypertensive Effect of Recombinant Renalase in Dahl Salt Sensitive (DSS) Rats,” 2010.
http://www.asn-online.org/education_and_meetings/renal_week/archives/
|
[25]
|
G. V. Desir, “Renalase Deficiency in Chronic Kidney Disease, and Its Contribution to Hypertension and Cardiovascular Disease,” Current Opinion in Nephrology and Hypertension, Vol. 17, No. 2, 2008, pp. 181-185.
doi:10.1097/MNH.0b013e3282f521ba
|
[26]
|
M. Schlaich, F. Socratous and N. Eikelis, “Renalase Plasma Levels Are Associated with Systolic Blood Pressure in Patients with Resistant Hypertension,” Journal of Hypertension, Vol. 28, 2010, pp. e434-e435.
doi:10.1097/01.hjh.0000379519.82971.02
|
[27]
|
Y. Wu, J. Xu, H. Velazquez, P. Wang, G. Li, D. Liu, et al., “Renalase Deficiency Aggravates Ischemic Myocardial Damage,” Kidney International, Vol. 79, No. 8, 2011, pp. 853-860. doi:10.1038/ki.2010.488
|
[28]
|
Q. Zhao, Z. Fan, J. He, S. Chen, H. Li, P. Zhang, et al., “Renalase Gene Is a Novel Susceptibility Gene for Essential Hypertension: A Two-Stage Association Study in Northern Han Chinese Population,” Journal of Molecular Medicine, Vol. 85, No. 8, 2007, pp. 877-885.
doi:10.1007/s00109-006-0151-4
|
[29]
|
R. Farzaneh-Far, G. V. Desir, N. B. Schiller and M. A. Whooley, “A Functional Polymorphism in Renalase
(Glu37Asp) Is Associated with Cardiac Hypertrophy, Dys- function, and Ischemia: Data from the Heart and Soul Study,” PLoS One, Vol. 5, No. 10, 2010, pp. e13496.
doi:10.1371/journal.pone.0013496
|
[30]
|
D. Ojea, R. Marin, E. Coto, et al., “Clinical and Genetic Basis of Hypertensive Nephrosclerosis,” Nefrologia, Vol. 30, No. 6, 2010, pp. 687-697.
|
[31]
|
A. S. Levey, J. Coresh, E. Balk, A. T. Kausz, A. Levin, M. W. Steffes, et al., “National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification,” Annals of Internal Medicine, Vol. 139, No. 2, 2003, pp. 137-147.
|
[32]
|
A. Fogo, J. A. Breyer, M. C. Smith, W. H. Cleveland, L. Agodoa, K. A. Kirk, et al., “Accuracy of the Diagnosis of Hypertensive Nephrosclerosis in African Americans: A Report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators,” Kidney International, Vol. 51, No. 1, 1997, pp. 244-252.
|
[33]
|
B. I. Freedman, P. J. Hicks, M. A. Bostrom, M. E. Cunningham, Y. Liu, J. Divers, et al., “Polymorphisms in the Non-muscle Myosin Heavy Chain 9 Gene (MYH9) Are Strongly Associated with End-stage Renal Disease Historically Attributed to Hypertension in African Americans,” Kidney International, Vol. 75, No. 7, 2009, pp. 736-745. doi:10.1038/ki.2008.701
|